Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy rep...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1077436/full |
| _version_ | 1828071781417615360 |
|---|---|
| author | Zong-Han Wang Wei Li Hao Dong Fujun Han |
| author_facet | Zong-Han Wang Wei Li Hao Dong Fujun Han |
| author_sort | Zong-Han Wang |
| collection | DOAJ |
| description | Chronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy represented is one of the most effective therapeutic approaches with the potential of better effect and prognosis. Natural killer (NK) cells are good options for immunotherapy as they can effectively mediate anti-tumor activity of immune system by expressing activating and inhibiting receptors and recognizing specific ligands on various tumor cells. NK cells are critical in the immunotherapy of CLL by enhancing self-mediated antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy and chimeric antigen receptor-natural killer (CAR-NK) cell therapy. In this article, we reviewed the features, working mechanisms, and receptors of NK cells, and the available evidence of the advantages and disadvantages of NK cell-based immunotherapies, and put forward future study directions in this field. |
| first_indexed | 2024-04-11T00:57:47Z |
| format | Article |
| id | doaj.art-890e5b681c8b49c88d45eacffc83afc2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T00:57:47Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-890e5b681c8b49c88d45eacffc83afc22023-01-04T21:20:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-01-011210.3389/fonc.2022.10774361077436Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemiaZong-Han Wang0Wei Li1Hao Dong2Fujun Han3Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of General Surgery, Second Affiliated Hospital of Jilin University, Changchun, Jilin, ChinaDepartment of Gastrointestinal Nutrition and Surgical Surgery, The Second Affiliated Hospital of Jilin University, Changchun, Jilin, ChinaCancer Center, The First Hospital of Jilin University, Changchun, Jilin, ChinaChronic lymphocytic leukemia (CLL) has become one of the most common hematological diseases in western countries, with an annual incidence of 42/100,000. Conventional chemotherapy and targeted therapeutic drugs showed limitations in prognosis or in efficiency in high-risk patients. Immunotherapy represented is one of the most effective therapeutic approaches with the potential of better effect and prognosis. Natural killer (NK) cells are good options for immunotherapy as they can effectively mediate anti-tumor activity of immune system by expressing activating and inhibiting receptors and recognizing specific ligands on various tumor cells. NK cells are critical in the immunotherapy of CLL by enhancing self-mediated antibody-dependent cytotoxicity (ADCC), allogeneic NK cell therapy and chimeric antigen receptor-natural killer (CAR-NK) cell therapy. In this article, we reviewed the features, working mechanisms, and receptors of NK cells, and the available evidence of the advantages and disadvantages of NK cell-based immunotherapies, and put forward future study directions in this field.https://www.frontiersin.org/articles/10.3389/fonc.2022.1077436/fullCLLNK cellsimmunotherapyreceptorsanti-tumor activity |
| spellingShingle | Zong-Han Wang Wei Li Hao Dong Fujun Han Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia Frontiers in Oncology CLL NK cells immunotherapy receptors anti-tumor activity |
| title | Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia |
| title_full | Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia |
| title_fullStr | Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia |
| title_full_unstemmed | Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia |
| title_short | Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia |
| title_sort | current state of nk cell mediated immunotherapy in chronic lymphocytic leukemia |
| topic | CLL NK cells immunotherapy receptors anti-tumor activity |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1077436/full |
| work_keys_str_mv | AT zonghanwang currentstateofnkcellmediatedimmunotherapyinchroniclymphocyticleukemia AT weili currentstateofnkcellmediatedimmunotherapyinchroniclymphocyticleukemia AT haodong currentstateofnkcellmediatedimmunotherapyinchroniclymphocyticleukemia AT fujunhan currentstateofnkcellmediatedimmunotherapyinchroniclymphocyticleukemia |